Boehringer Navigates ‘Impractical’ Nintedanib Surveillance Plan In India
Executive Summary
Boehringer seeks tweaks in the surveillance plan for nintedanib in India amid disinclination among some physicians to participate in the study. Some experts though believe that the Indian regulatory apparatus should, in general, specify “strict guidance” on all protocol review requests.
You may also be interested in...
Keytruda’s Catch-22 Situation In India Amid Compliance Questions
Merck & Co’s immuno-oncology therapy Keytruda appears be facing a rather paradoxical situation in India, after an expert panel noted that the US multinational had failed to comply with Phase IV study requirements pertaining to the product in the country.
India IPR Realities: Pharma, Legal Heads Discuss Winds Of Change, ‘Damocles Sword’
Leaders from Novartis, Bayer, Sun Pharma, the Indian Pharmaceutical Alliance, Médecins Sans Frontières and Anand and Anand discuss India’s evolving intellectual property rights landscape, including pre-grant oppositions, enforcement action and other realities. Concerns around evergreening, restrictions on patent-eligible subject matter and compulsory licensing were also key talking points at a recent conference in Hyderabad.
India IPR Wheels Are Turning: Novartis, Bayer, Sun, Legal Heads Discuss Realities
Leaders from Novartis, Bayer, Sun Pharma, the Indian Pharmaceutical Alliance, Médecins Sans Frontières and Anand and Anand discuss India’s evolving intellectual property rights landscape, including pre-grant oppositions, enforcement action and other realities. Concerns around evergreening, restrictions on patent-eligible subject matter and compulsory licensing were also key talking points at a recent conference in Hyderabad.